🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Breast Carcinoma

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928Phase 17 sites📍 Duarte📍 La Jolla📍 Aurora Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: bulumtatug fuvedotin, bulumtatug fuvedotin Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) NCT04434040Phase 27 sites📍 San Francisco📍 Chicago📍 New Lenox Dana-Farber Cancer Institute · Tests: Atezolizumab, Sacituzumab govitecan A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. NCT07443774n/a1 site📍 Grenoble University Hospital, Grenoble Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial NCT07474090NA4 sites📍 Winston-Salem📍 Winston-Salem📍 Richmond Wake Forest University Health Sciences · Tests: Exercise Intervention, Educational Intervention, Supportive Care, Biospecimen Collection, Magnetic Resonance Imaging A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab The PREDICT Registry: NCT03448926n/a30 sites📍 Scottsdale📍 La Jolla📍 San Mateo PreludeDx · Tests: Treatment recommendation surveys, 7-gene biosignature Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie NCT07357311n/a1 site📍 Paris Institut Curie De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) NCT04852887Phase 3832 sites📍 Birmingham📍 Mobile📍 Kingman NRG Oncology · Tests: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozo… A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764Phase 11 site📍 Rochester Mayo Clinic · Tests: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Reson… 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer NCT04529044Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients NCT06780748Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Identification rate of sentinel lymph node Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy NCT05866458n/a27 sites📍 Cudgen📍 Liverpool📍 North Sydney Ontario Clinical Oncology Group (OCOG) Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Bortezomib (B), Cisplatin (CDDP), Bortezomib (B), Bortezomib (B), Cisplatin (CDDP) A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer NCT06452706Phase 216 sites📍 Bozhou📍 Chuzhou📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Computed Tomography, Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomogr… A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites📍 Birmingham📍 Phoenix📍 Beverly Hills Puma Biotechnology, Inc. · Tests: Alisertib, Endocrine therapy Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors NCT05283330Phase 18 sites📍 Chicago📍 Iowa City📍 Lexington Orano Med Theranostics, SAS · Tests: ²¹²Pb-DOTAM-GRPR1 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment NCT07467330Phase 31 site📍 Fuzhou Fujian Cancer Hospital · Tests: dalpiciclib + capecitabine + endocrine therapy, dalpiciclib + endocrine therapy PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS NCT05792150n/a71 sites📍 Baden-Baden📍 Pforzheim📍 Stuttgart Women's Cancer Study Group GmbH EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) NCT06401421n/a58 sites📍 Anchorage📍 Palo Alto📍 Torrance Exact Sciences Corporation · Tests: ctDNA MRD test Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer NCT06217874n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers NCT07545122Phase 16 sites📍 Wahroonga📍 Westmead📍 Gold Coast Context Therapeutics Inc. · Tests: CT-202 Study on Recurrent Breast Cancer and Repeated Radiation Therapy NCT06704659NA2 sites📍 Helsinki📍 Turku Turku University Hospital · Tests: Breast conserving surgey and radiotherapy, Mastectomy A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates NCT07520760Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Eribulin in Combination with Anlotinib Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774Phase 3226 sites📍 Jonesboro📍 Auburn📍 Berkeley National Cancer Institute (NCI) · Tests: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy